Immune suppression in the tumor microenvironment may be introduced and maintained through programmed cell death protein (PD‐1)/programmed death‐ligand 1 (PD‐L1) suppressing the functions of T cells from a broad range of cancer types, including HNSCC.5, 6 Few studies in myeloma cells concerning the markers between immune suppression and drug resistance were reported.7, 8. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.